CHIMERIC THERAPEUTICS LIMITED - AGM Information 2021

==> picture [665 x 116] intentionally omitted <==

Annual General Meeting Corporate Update I November 22, 2021

CHIMERIC THERAPEUTICS

CORPORATE SNAPSHOT

==> picture [55 x 348] intentionally omitted <==

The ASX leader in cell therapy as the only clinical stage cell therapy company

Lead asset, CHM 1101 (CLTX CAR T) advancing in a phase 1 clinical trial with promising early clinical data

CHM 2101 (CDH17 CAR T) making rapid progress to Phase 1 in 2022

Further advancing pipeline development with innovative cell therapies

Industry leading expertise and experience in cell therapy development

Founded in 2020 and listed on the ASX (CHM) in January 2021 with an oversubscribed raise of $35M

==> picture [421 x 182] intentionally omitted <==

----- Start of picture text -----

0.4 0.37
0.35 0.32 0.31 0.34 0.32
0.31
0.3 0.28 0.27 0.31
0.25
0.2
0.2
0.15
0.1
0.05
0
January February March April May June July August September October
Share Price AUS ($)
----- End of picture text -----

Net Cash: AUS $18M (Sept 21) Board / Mgmt. Ownership: 30%

Market Cap: AUS ~$110M Shares on Issue: 330 M

OUR MISSION

To Bring the Promise of Cell Therapy to Life

==> picture [114 x 150] intentionally omitted <==

==> picture [115 x 152] intentionally omitted <==

Traditional drug development focuses on delaying disease progression- not on a cure. We believe that novel cellular therapies have the promise to cure cancer.

==> picture [122 x 169] intentionally omitted <==

“ ~~These are patients with an abysmal progn~~ osis, really without hope and now with CAR T therapy we’re really able to give them a chance. This is a revolution. It's a revolution in cancer care. This is the tip of the iceberg,”

Fred Locke, MD Moffit Cancer Center

Our mission is to to bring that promise to life for more patients with cancer.

“With about 6 months to live, I got a call asking if I wanted to join a CAR T clinical trial. I believe that call saved my life .”

Dimas Padilla Cancer Survivor

CELL THERAPY INVESTMENT LANDSCAPE

Cell therapy is the most active investment sector in biotech today with ~$20B in financing in 2020

The global market for cell therapies is estimated to reach between USD $8-9 billion by 2026

In the past 18-24 months, 16 of the largest pharmaceutical companies have added cell and gene therapy products to their portfolio

ACQUISITIONS

PARTNERSHIPS

IPO’s

Gilead acquisition $11.9B of Kite

Celgene acquisition $9B of Juno

Astellas acquisition $665M of Xyphos

Kite acquisition of Cell Design Labs $567M

Janssen & Fate $3B Kite & Shoreline $2.3B Vertex & CRISPR $900M Eli Lilly & Precision $525M Merck & Artiva $1.8B Roche & Adaptimmune $3B

Janssen & Fate

Sana Biotech $675M

Lyell $425M

CARsgen $400M

Instil Bio $368M Graphite Bio $273M Century Tx $243M

CHIMERIC PORTFOLIO DEVELOPMENT STRATEGY

Focused on building a diversified cell therapy pipeline with cutting edge innovation

==> picture [705 x 356] intentionally omitted <==

----- Start of picture text -----

Novel Designs
Alternative
T Cells NK Cells
Cell Types
Alternative
Individualized Off the Shelf
(autologous) (allogeneic)
Cell Sources
----- End of picture text -----

CHIMERIC PIPELINE

2 NOVEL CAR T CELL THERAPIES

==> picture [629 x 375] intentionally omitted <==

==> picture [60 x 60] intentionally omitted <==

Ongoing phase 1 clinical trial 2 additional phase 1 clinical trials planned for 2022 across Development 7 different types of cancer

WHAT IS CAR T CELL THERAPY?

Cell therapy is the transfer of live cells into a patient to treat or cure a disease.

C himeric A ntigen R eceptor T (CAR T) Cell Therapy is a type of cell therapy that modifies a patient’s own immune cells (T-cells) to use directly against their cancer.

==> picture [371 x 203] intentionally omitted <==

----- Start of picture text -----

CAR T Cell
Leukapheresis blood Infusion into individual
draw) from individual patient
patient
----- End of picture text -----

A patient’s blood is taken, and their T cells are engineered to express a chimeric antigen receptor that recognizes specific structures (antigens) on the surface of cancer cells.

==> picture [352 x 215] intentionally omitted <==

----- Start of picture text -----

Chimeric Antigen
Receptors
Cancer
Antigen
Target
Cancer
CAR T Cell
Cell
----- End of picture text -----

Once the CAR T cells have been infused into a patient, they seek out the antigen targets on cancerous cells. The CAR T cell then binds to the cancerous cell and sends a signal to kill the cancerous cell.

CHM 1101: CHLOROTOXIN (CLTX) CAR T

CHM 1101 (CLTX CAR T) was designed and studied preclinically in glioblastoma , one of the most lethal types of cancer.

==> picture [340 x 320] intentionally omitted <==

Patients with glioblastoma have an expected survival of ~12 months and only . 38% survive more than one year

CHM 1101 uniquely uses Chlorotoxin , a peptide derived from deathstalker scorpion venom to target the glioblastoma cells in patients.

In preclinical studies CHM 1101 was shown to be able to find, bind and kill glioblastoma cancer cells better than other immunotherapy targets.

Chimeric holds a global exclusive license to CLTX CAR T. CLTX CAR T has a long life, composition of matter intellectual property profile expiring 2036.

CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial Advancing Towards Higher Dose Levels

Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan

Phase 1 Clinical Trial Design: 4 dose levels and 2 routes of administration

==> picture [672 x 240] intentionally omitted <==

----- Start of picture text -----

DOSE LEVEL 1 DOSE LEVEL 2
DOSE LEVEL 3 DOSE LEVEL 4
COMPLETE IN PROGRESS
Intratumoral Administration Intratumoral and Intraventricular Intratumoral and Intraventricular Intratumoral and Intraventricular
Administration Administration Administration
ICT Administration ICT & ICV Administration ICT & ICV Administration ICT & ICV Administration
Total dose: 44 X 10 [6] Total dose: 88 X 10 [6] Total dose: 220 X 10 [6] Total dose: 440 X 10 [6]
----- End of picture text -----

Approximately 18 -36 patients with recurrent or progressive GBM over 24 months

CHM 1101 (CLTX CAR T) Positive Initial Phase 1 Clinical Data

==> picture [203 x 68] intentionally omitted <==

==> picture [265 x 250] intentionally omitted <==

75% Disease Control Rate (DCR)

CLTX CAR T demonstrated a 75% Disease Control Rate in the 1[st] dose level

No Dose Limiting Toxicities CLTX CAR T cells were generally well tolerated with no dose limiting toxicities

Persistence of Cells CLTX CAR T cells were shown to persist throughout treatment

CHM 1101 (CLTX CAR T) SNO Presentation Data Update (Nov 19, 2021)

Efficacy Efficacy Safety Research

75% Disease control rate (DCR) with up to 8 weeks of durability Regional control of tumour recurrence where CLTX CAR T cells were infused No dose limiting toxicities and no cytokine release syndrome Basic research data to support aggressive disease treatment and melanoma expansion

CHM 1101 (CLTX CAR T) Clinical Development Program

FDA clearance for Chimeric CLTX IND in August 2021 enables accelerated and expanded clinical development in 2022

==> picture [791 x 323] intentionally omitted <==

----- Start of picture text -----

Preclinical Phase 1
CLTX CAR T
City of Hope Clinical Trial Site
Glioblastoma
Clinical Trial Clinical Trial Site. #2
Clinical Trial Site. #3
Melanoma Advance to Clinic
CLTX CAR T
Solid Tumour Colorectal Cancer Advance to Clinic
Clinical Trial
Prostate Cancer Advance to Clinic
Currently In Progress
Planned for 2022
----- End of picture text -----

CHM 2101 (CDH17 CAR T) PROMISE FOR GASTROINTESTINAL CANCERS

Exclusive Chimeric licensing from the University of Pennsylvania

Competitive licensing process for the novel 3[rd] generation CDH17 CAR T from world renowned cell therapy centre

==> picture [107 x 107] intentionally omitted <==

----- Start of picture text -----

CDH17 CAR T
----- End of picture text -----

Dramatic Preclinical Efficacy

Preclinical evidence in neuroendocrine tumours demonstrated safety with complete tumour eradication with no relapse

Phase 1 Clinical Trial Planned for 2022

Phase 1 basket trial planned in gastrointestinal (GI) cancers; colorectal, pancreatic and gastric cancer and neuroendocrine tumours

CDH17 CAR T

ACCELERATING DEVELOPMENT TOWARDS THE CLINIC

CDH17 clinical manufacturing readiness
Completed critical first milestone on path to clinical manufacturing readiness in 2022
CDH17 viral vector manufacturing
CDH17 preclinical data in •
neuroendocrine (NET) and CHM IND filing for phase 1
gastrointestinal tumours clinical trial (colorectal, pancreatic and gastric) • Phase 1 clinical trial initiation at University of Pennsylvania with expansion to additional clinical sites
Hua laboratory at Penn advancing preclinical validation

==> picture [411 x 119] intentionally omitted <==

----- Start of picture text -----

2021 2022
----- End of picture text -----

==> picture [576 x 49] intentionally omitted <==

----- Start of picture text -----

1H 2H
----- End of picture text -----

CHIMERIC ONGOING PIPELINE DEVELOPMENT

Further pipeline development is a key focus for 2021-2022

==> picture [648 x 355] intentionally omitted <==

----- Start of picture text -----

Novel Designs
T Cells
NK Cells
Individualized
(autologous)
CLTX CLTX CDH17
Phase 1 CAR T
CAR T CAR T
ongoing in
brain cancer
Phase 1 Ongoing Phase 1 Planned 2022 Off the Shelf
(allogeneic)
----- End of picture text -----

CHIMERIC MANAGEMENT TEAM

GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

==> picture [138 x 200] intentionally omitted <==

----- Start of picture text -----

Jennifer
CHOW
Chief Operating
Officer
----- End of picture text -----

==> picture [25 x 21] intentionally omitted <==

==> picture [38 x 17] intentionally omitted <==

==> picture [31 x 16] intentionally omitted <==

• KITE PHARMA

Head of Global Marketing, Commercial Operations and Analytics

• CELGENE

Global Cell Therapy Commercial Lead

==> picture [139 x 201] intentionally omitted <==

----- Start of picture text -----

Dr Syed
RIZVI
Chief Medical Officer
----- End of picture text -----

==> picture [25 x 21] intentionally omitted <==

==> picture [46 x 22] intentionally omitted <==

==> picture [49 x 8] intentionally omitted <==

LEGEND BIOTECH
VP, Clinical Development and Medical Affairs

• CELGENE

Global Cell Therapy Medical Affairs Lead

==> picture [139 x 200] intentionally omitted <==

----- Start of picture text -----

Dr Eliot
BOURK
VP, Business and
Corporate Development
----- End of picture text -----

==> picture [25 x 21] intentionally omitted <==

==> picture [38 x 17] intentionally omitted <==

==> picture [40 x 10] intentionally omitted <==

KITE PHARMA

Head of Early Commercial Development

CELGENE

Global Cell Therapy Commercial Strategy and Next Generation Platforms

==> picture [139 x 201] intentionally omitted <==

----- Start of picture text -----

Dr Li
REN
VP, Technical
Operations
----- End of picture text -----

==> picture [49 x 29] intentionally omitted <==

==> picture [23 x 21] intentionally omitted <==

Global Manufacturing, Cell Therapy Development and Operations

CELGENE

CAR T CMC and Technology Development

==> picture [262 x 353] intentionally omitted <==

----- Start of picture text -----

Development of over
25 CELLTHERAPIES
including
OF THE
FDA-APPROVED
CAR T CELL THERAPIES
4/5
----- End of picture text -----

THE ASX LEADER IN CELL THERAPY

Two novel cell therapy assets from world renowned institutions, University of Pennsylvania and City of Hope
CLTX CAR T current phase 1 clinical trial advancing in glioblastoma with encouraging early data; 2[nd] clinical trial planned for 2022 in solid tumours
CDH17 CAR T broad phase 1 clinical program planned for 2022 in 4 gastrointestinal cancers
Attractive near term opportunities for strategic pipeline development
Industry leading management team with extensive experience and expertise in cell therapy

==> picture [260 x 268] intentionally omitted <==

----- Start of picture text -----

Potential Value
Realization Pathways
Sale of
Strategic
the Company
Partnership
Develop
Independently
----- End of picture text -----

AI assistant

CHIMERIC THERAPEUTICS LIMITED AGM Information 2021

64648_rns_2021-11-21_000ec4da-9be5-4dd1-af80-2e7159338294.pdf